Anti-DOC2A monoclonal antibody
Pre-made anti-DOC2A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to DOC2A/DOC2A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2461-Ab-1/ GM-Tg-hg-IP2461-Ab-2 | Anti-Human DOC2A monoclonal antibody | Human |
GM-Tg-rg-IP2461-Ab-1/ GM-Tg-rg-IP2461-Ab-2 | Anti-Rat DOC2A monoclonal antibody | Rat |
GM-Tg-mg-IP2461-Ab-1/ GM-Tg-mg-IP2461-Ab-2 | Anti-Mouse DOC2A monoclonal antibody | Mouse |
GM-Tg-cynog-IP2461-Ab-1/ GM-Tg-cynog-IP2461-Ab-2 | Anti-Cynomolgus/ Rhesus macaque DOC2A monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2461-Ab-1/ GM-Tg-felg-IP2461-Ab-2 | Anti-Feline DOC2A monoclonal antibody | Feline |
GM-Tg-cang-IP2461-Ab-1/ GM-Tg-cang-IP2461-Ab-2 | Anti-Canine DOC2A monoclonal antibody | Canine |
GM-Tg-bovg-IP2461-Ab-1/ GM-Tg-bovg-IP2461-Ab-2 | Anti-Bovine DOC2A monoclonal antibody | Bovine |
GM-Tg-equg-IP2461-Ab-1/ GM-Tg-equg-IP2461-Ab-2 | Anti-Equine DOC2A monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP2461-Ab-1/ GM-Tg-hg-IP2461-Ab-2; GM-Tg-rg-IP2461-Ab-1/ GM-Tg-rg-IP2461-Ab-2; GM-Tg-mg-IP2461-Ab-1/ GM-Tg-mg-IP2461-Ab-2; GM-Tg-cynog-IP2461-Ab-1/ GM-Tg-cynog-IP2461-Ab-2; GM-Tg-felg-IP2461-Ab-1/ GM-Tg-felg-IP2461-Ab-2; GM-Tg-cang-IP2461-Ab-1/ GM-Tg-cang-IP2461-Ab-2; GM-Tg-bovg-IP2461-Ab-1/ GM-Tg-bovg-IP2461-Ab-2; GM-Tg-equg-IP2461-Ab-1/ GM-Tg-equg-IP2461-Ab-2 |
Products Name | Anti-DOC2A monoclonal antibody |
Format | mab |
Target Name | DOC2A |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-DOC2A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP2461-Ag-1 | Recombinant multi-species DOC2A/ Doc2 protein |
Target information
Target ID | GM-IP2461 |
Target Name | DOC2A |
Gene ID | 8448,13446,65031,707895,489945,101100270,528120,100066024 |
Gene Symbol and Synonyms | Doc2,DOC2A |
Uniprot Accession | Q14183,P70611 |
Uniprot Entry Name | DOC2A_HUMAN,DOC2A_RAT |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000149927 |
Target Classification | N/A |
The target: DOC2A, gene name: DOC2A, also named as Doc2. There are at least two protein isoforms of the Double C2 protein, namely alpha (DOC2A) and beta (DOC2B), which contain two C2-like domains. DOC2A and DOC2B are encoded by different genes; these genes are at times confused with the unrelated DAB2 gene which was initially named DOC-2. DOC2A is mainly expressed in brain and is suggested to be involved in Ca(2+)-dependent neurotransmitter release. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.